Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.

Using the prespecified ApoE genotype-based analyses, we observed a highly significant reduction in brain amyloid on the composite measure and in five of six cortical regions of interest among ApoE4 noncarriers.

also in 132,142 other papers